human VEGF (Vascular endothelial growth factor) antibody: purified antibody

Contents: Affinity Purified anti-human VEGF polyclonal
Catalog Number: 14-6751
Formulation: 200 µg/ml rabbit polyclonal IgG in PBS containing 0.1 % sodium azide and 0.2% gelatin.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
Clone: Polyclonal
Isotype: Rabbit IgG

Prices for This Product*
Cat. No.	Size	Price	Qty	Action
14-6751-63	10 ug	$30
14-6751-81	50 ug	$115

*International customers: Please contact your distributor for region specific pricing.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
14-6751	Purified anti-human VEGF polyclonal	N/A	N/A	WB

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

The polyclonal antibody reacts with human VEGF. The antibody was raised against a peptide mapping to a domain near the amino terminus of Human VEGF. The vascular endothelial growth factor (VEGF) family currently includes VEGF (VEGF-A), VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF (1). VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis (2). Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process (3&4). To date 5 different isoforms of VEGF have been described, VEGF 121, VEGF 145, VEGF 165, VEGF 165b, and VEGF 189(4&5). These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells (5).

Applications Reported

For research use only, not for diagnostic or therapeutic use. Purified anti-human VEGF poly has been reported for use in immunoblotting (WB).

Applications Tested

Purified anti-human VEGF poly has been tested by immunoblotting (WB).

References

1. Matsumoto T, Claesson-Welsh L. 2001. VEGF receptor signal transduction. Sci STKE 112:RE21.
2. Shibuya M. 2001. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26(1):25-35.
3. Hasan J, Jasyson GC. 2001. VEGF antagonists. Expert Opin Biol Ther 1(4):703-18.
4. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. 2002. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62(14):4123-31.
5. Neufel G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB 13(1):9-22.

Related Products

Cat. 18-8816 Rabbit TrueBlot™: Horseradish Peroxidase (HRP) anti-rabbit IgG
Cat. 66-P751 Blocking Peptides for anti-human VEGF polyclonal